Program
Ramucirumab
Also written as “IMC-1121B (ramucirumab)”, “Ramucirumab (IMC-1121B)” and “IMC-1121B”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Stomach Neoplasms · Neoplasms · Carcinoma, Hepatocellular · Breast Neoplasms, led by 6 companies.
Drug pageRamucirumab: every studyMany companies study it; this page follows only the 58 they lead. All 109 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lillyits history only | 533 open or running | phase 3since Jun 20, 2008 | Aug 13, 2007 | May 2027phase 2 · NCT05999994 |
| Arog Pharmaceuticalsits history only | 10 open or running | phase 1since Jun 14, 2017 | Jun 14, 2017 | none ahead |
| AstraZenecaits history only | 11 open or running | phase 2since May 5, 2025 | May 5, 2025 | Feb 23, 2029phase 2 · NCT06996782 |
| Innovent Biologics | 10 open or running | phase 3since Dec 3, 2020 | Dec 3, 2020 | none ahead |
| Merckits history only | 11 open or running | phase 2since May 31, 2024 | May 31, 2024 | May 9, 2028phase 2 · NCT06445972 |
| Sino Biopharmaceuticalits history only | 10 open or running | phase 1since Mar 24, 2023 | Mar 24, 2023 | none ahead |
Also a collaborator on its studies: Daiichi Sankyo and Parexel.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Innovent Biologics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 3, 2020First study: phase 3 study in Gastric AdenocarcinomaFirst studyNCT04675983 · 36 enrolled · China
TargetBeta
“A recombinant, fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with antiangiogenesis activity”NCIt, by rule
“Vascular endothelial growth factor receptor 2 inhibitor”ChEMBL 37, by rule
Other programs on KDR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| lenvatinibrule | Eisai | phase 4 | 81 |
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| regorafenibrule | Bayer | phase 4 | 40 |
| cabozantinibrule | Exelixis | phase 4 | 36 |
| apatinibrule | Jiangsu HengRui Medicine | phase 3 | 47 |
| Axitinibrule | Pfizer | phase 3 | 45 |
| anlotinibrule | Sino Biopharmaceutical | phase 3 | 40 |
| vorolanibrule | Betta Pharmaceuticals | phase 3 | 24 |
| zanzalintinibrule | Exelixis | phase 3 | 17 |
| chiauranibrule | Chipscreen Biosciences | phase 3 | 15 |
| Aurora B/VEGFR/FGFR Inhibitor AL8326rule | advenchen-laboratories-nanjing-ltd | phase 3 | 8 |
| AXL/FLT3/VEGFR2 Inhibitor KC1036rule | beijing-konruns-pharmaceutical-co-ltd | phase 3 | 7 |
Studies
The one study Innovent Biologics leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT04675983Gastric Adenocarcinoma · China | 3 | Terminated | Feb 12, 2023 | 36 |
How it is read
Names in the registry
- “Ramucirumab”, 36 entries
- “IMC-1121B (ramucirumab)”, 4 entries
- “Ramucirumab (IMC-1121B)”, 4 entries
- “IMC-1121B”, 4 entries
- “ramucirumab (IMC-1121B)”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Stomach Neoplasms, 7 studies
- Neoplasms, 5 studies
- Carcinoma, Hepatocellular, 4 studies
- Breast Neoplasms, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.